The Journey of an FDA-Approved CDx for Rare Fusions: Rozlytrek CDx Case Study

By | 27 May 2025
  • Genentech’s first FDA-approved tumor-agnostic medicine designed to target both ROS1 and NTRK 
  • Roche/Genentech and Foundation Medicine (FMI) CDx collaboration: Comprehensive genomic testing is critical to identify patients with rare gene fusions 
  • Understanding of the techniques for NTRK testing in clinical practiceÂ